Bausch Health Companies Inc., via subsidiaries Bausch Health Americas and BHC Lyon Merger Sub, filed a Schedule TO-C on 29 July 2025 announcing its intent to commence a third-party tender offer for all outstanding shares of DURECT Corporation (DRRX) common stock.
The offer has not yet begun and the filing discloses no purchase price, premium, timetable or financing details. Full terms will be provided in forthcoming Schedule TO documents, while DURECT will respond with a Schedule 14D-9. All materials will be accessible on the SEC’s website and both companies’ investor portals.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.